Colgate Has Raised Its Dividend for 63 Years. These 3 Staples Stocks Offer Income

Published November 19, 2026, 3:47pm ET · 5 min read

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

A close-up photograph of multiple financial charts and graphs on white paper, held by a blue clipboard. The word 'DIVIDENDS' is printed in large, bold black letters across the center sheet. A green paperclip holds additional chart papers, and a neon yellow highlighter rests in the foreground. The charts use green and yellow bars along with orange line graphs to illustrate data points.
Financial charts and the prominent word "DIVIDENDS" underscore the importance of strategic investment in building passive income streams for long-term financial stability. © Jack_the_sparow / Shutterstock.com

Toothpaste, pain relievers, diapers, and canned meat end up in shopping carts whether the economy is booming or sliding. That repeat demand is what lets a company keep paying dividends through recessions, and the best of the three names below has a record that spans generations: Colgate-Palmolive (NYSE:CL | CL Price Prediction) has raised its dividend for 63 consecutive years. Below is how safe each payout looks today, starting with a change every Kenvue shareholder needs to know about.

Kimberly-Clark: Kenvue’s Tylenol and Band-Aid Now Pay Through Huggies’ Parent

Kenvue no longer trades independently. Kimberly-Clark (NASDAQ:KMB) completed the acquisition on November 2, 2026, and Kenvue was delisted from the New York Stock Exchange. Kenvue holders received $3.50 in cash and 0.14625 Kimberly-Clark shares for each share they owned. Kenvue’s last standalone quarterly dividend was $0.21 per share, paid October 2, 2026. Today, owning Tylenol, Neutrogena, and Listerine means owning them alongside Huggies, Kleenex, Cottonelle, and Scott inside one company.

Dividend safety: Kimberly-Clark yields 4.72%, which qualifies as high-yield. The quarterly payout rose from $1.26 to $1.28 starting with the March 6, 2026 ex-dividend date. The board declared the next $1.28 payment on November 11, 2026, payable January 5, 2027. The company has paid a dividend for 92 consecutive years and raised it for 54 consecutive years. Reported trailing EPS of $5.24 looks better than it is because it includes a $4.33-per-share gain from contributing its international tissue business to a joint venture. Adjusted EPS over the last four quarters totals $7.65, which puts the $5.10 trailing dividend at roughly 66.7% of earnings. That is comfortable coverage. Free cash flow was thinner last year: $1.639 billion for 2025, down 34.78% as capital spending rose to $1.138 billion.

Bull case: Kenvue came into the deal growing. Its final quarter as a public company produced net sales of $3.886 billion, up 3.2%[1], gross margin of 59.5%, and a fourth consecutive quarter of net and organic sales growth. Kimberly-Clark’s own third-quarter adjusted EPS of $1.70 beat the $1.65 consensus, and the stock trades at about 15 times forward earnings. Mike Hsu, chief executive at the time of the release, called the closing “a defining moment in the 154-year history of Kimberly-Clark.”

Risk: The company says the Kenvue acquisition will substantially increase its indebtedness. Paying down that debt will compete with dividend growth for cash, so raises could stay small while the company works off its leverage.

Colgate-Palmolive: Six Decades of Raises Funded by Toothpaste and Pet Food

Colgate sells oral care, personal care and home cleaning products, plus Hill’s Science Diet and Prescription Diet pet food. Its scale in the core category is hard to match: a 41.4% global share in toothpaste year to date.

Dividend safety: The stock yields 2.11%, the lowest in this group and well below high-yield territory. Here you are paying for durability. The quarterly dividend rose from $0.52 to $0.53 starting with the April 20, 2026 ex-dividend date, and the latest payment went out November 13, 2026. On trailing GAAP EPS of $2.57, the payout ratio is 81.7%. That figure is distorted by a $919 million impairment on the Filorga skin care business and by restructuring charges of $327 million[2] so far this year. Measured against the last four quarters of Base Business EPS, the payout is a much safer 54.4%. Cash flow tells the same story: 2025 free cash flow of $3.634 billion covers the roughly $1.68 billion annual dividend bill about 2.2 times. Years of buybacks have shrunk shareholders’ equity to just $288 million against $16.102 billion in liabilities, so cash generation is the real safety net here. Book value offers almost none.

Bull case: Momentum is improving. Third-quarter organic sales rose 3.6%[2], with volume up 1.7% and pricing up 2.0%. Base Business EPS of $0.97[2] beat the $0.93 consensus, the sixth consecutive beat. Management raised its full-year Base Business EPS growth outlook to 5% to 7%[2]. CEO Noel Wallace said the quarter delivered “another strong quarter of broad-based top- and bottom-line growth.” A dividend that keeps rising slowly on a widening earnings base is the trait income-focused investors tend to look for.

Risk: North America is losing ground. Volume there fell 3.7% in the third quarter, and operating profit dropped 11%, a sign that cheaper store brands and cautious shoppers are pressuring Colgate’s home market.

Hormel Foods: Biggest Yield of the Group, With a Coverage Question

Hormel Foods (NYSE:HRL) sells packaged meats and pantry foods under brands like SPAM, Skippy, Planters, Jennie-O, Applegate and Hormel Black Label. It also runs a large foodservice business that supplies restaurants and institutions.

Dividend safety: Hormel yields 5.17%. That is high-yield territory, though short of ultra-high-yield. The quarterly dividend rose from $0.29 to $0.2925 beginning with the January 12, 2026 ex-dividend date, and the latest payment went out November 16, 2026. When announcing that increase, then-CEO Jeff Ettinger said: “This marks an impressive milestone: 60 years of uninterrupted dividend increases at Hormel Foods.” Hormel is also a member of the S&P 500 Dividend Aristocrats. Coverage is where it gets harder. Trailing GAAP EPS of $0.64 implies a 182.5% payout, because results absorbed a $56 million[3] Brazil divestiture loss, a $48.2 million Indonesia impairment, and a $37.5 million antitrust settlement. Against adjusted EPS guidance of $1.45 to $1.51[3], the payout falls to 77.5% to 80.7%. Third-quarter free cash flow of about $172.4 million covered the $161 million[3] returned to shareholders. Fiscal 2025 free cash flow of roughly $534.3 million, however, fell short of the roughly $643.9 million annual dividend bill at today’s rate. Hormel’s balance sheet gives it room to absorb that gap: $839.6 million[3] in cash, and fiscal 2025 liabilities of $5.477 billion against $7.916 billion in equity.

Bull case: Recovery is visible in the numbers. Foodservice posted its 12th consecutive quarter[3] of organic growth, and adjusted operating margin widened to 9.0% from 8.4%. Third-quarter operating cash flow climbed 53.54%[3], and management raised its adjusted EPS outlook to 6% to 10% growth. The stock trades at about 15 times forward earnings after falling 36.07% over five years, a decline that has pushed the yield higher. Shares outperformed competitors in Wednesday’s trading.

Risk: Commodity input costs can swing Hormel’s profits quickly. Last year, inflation in protein costs forced management to cut its fiscal 2025 adjusted EPS outlook from $ 1.58 to $ 1.68, to $ 1.43 to $ 1.45. Hormel declared last year’s raise on November 24, 2025, so this year’s declaration is the next signal of the board’s confidence.

Matching Each Staple to Your Income Needs

All three companies sell products people keep buying in a downturn, and all three have raised their dividends for decades. They differ in what they ask of the investor. Colgate offers the strongest cash coverage at the lowest yield, which suits retirees who prioritize reliable raises over current income. Kimberly-Clark and Hormel pay more today in exchange for debt from the Kenvue deal and tighter cash coverage, respectively, which makes them better suited to income investors willing to follow those two issues closely.

Contact [email protected] for any questions or corrections.

Chris Lange

Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.

His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.

When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.

All articles →

Sources

  1. Kenvue Form 8-K (Q3 FY2026)U.S. Securities and Exchange Commission
  2. Colgate-Palmolive Company Form 8-K (Q3 FY2026)U.S. Securities and Exchange Commission
  3. Hormel Foods Form 8-K (Q3 FY2026)U.S. Securities and Exchange Commission